Product Categories
Store Links




 

Nicotine Explained

Nicotine Explained

While we are keen proponents of the e-cigarette, nicotine makes us nervous.
Nicotine, in its pure form, is one of the most lethal poisons known to man.
While relatively few people get nicotine poisoning via a cigarette, as most of the nicotine is burnt in the process of smoking, tobacco gatherers regularly get sick from nicotine leaching from wet tobacco leaves onto their skin.
The symptoms are not nice – they include vomiting, palpitations and tachycardia.
A serious case could be followed by coma and death.
Somewhere between 30 and 60 mg of nicotine are needed to kill someone and hopefully, with its unpleasant taste and sharp odour, a drinker would notice it before it killed them.
As the E-liquid carried by vapers is not in a pure form, fatalities in adults are pretty unlikely.


Both our Propylene Glycol (PG) and Vegetable Glycerin (VG) nicotine bases, are pharmacuetical grade, UK sourced, unflavoured nicotine bases, at 52mg/nl strength
Sourced to use for mixing your own E-liquid


The nicotine in our ready mixed E-liquid, is luted down to 24mg/ml 18mg/ml and 16mg/ml strength and comes from reputable manufacturers
(By luted down we mean, due to the nicotine in our E-liquids being mixed with PG, VG and flavouring)

Eventhough the nicotine in ready mixed E-liquid, is still a toxin it is not as dangerous/ toxic as nicotine in its purest form.
Though only to be used by people that suffer from a nicotine addiction

Nicotine can be found in many plants and even vegetables, so nicotine only coming from a tobacco plant alone is a myth.

NOTE: All liquids should be kept in a dark cool environment
Always dilute this product
Toxic if swallowed Very toxic in contact with the skin,
After contact with skin/ eyes, wash immediately with plenty of water.
Wear suitable clothing and gloves
Do not use it if you are pregnant, and/ or breast feeding
Toxic to aquatic organisms, may cause long term adverse effects in aquatic environment.
In case of an accident, or if you feel unwell, seek medical advice immediately, and show the label provided on the bottle
Keep locked up, and out of reach of children.
This material, and the container must be disposed of in a safe way

Nicotine From Wikipedia,
the free encyclopaedia
This article is about the chemical Nicotine.


Systematic (IUPAC) name

3-[(2S)-1-methylpyrrolidin-2-yl]pyridine

Clinical data

Trade names

Nicorette, Nicotrol

AHFS/Drugs.com

monograph

Pregnancy cat.

D (US)

Legal status

Unscheduled (AU) GSL (UK) OTC (US)

Dependence liability

High

                       


Routes

smoked (as smoking tobacco, mapacho, etc.), insufflated (as tobacco snuff or nicotine nasal spray), chewed (as nicotine gum, tobacco gum or chewing tobacco), transdermal (as
nicotine patch, nicogel or topical
tobacco paste),
intrabuccal (as
dipping tobacco, snuffs, dissolvable tobacco or creamy snuff), vaporized (as electronic cigarette, etc.), directly inhaled (as nicotine inhaler), oral (as nicotini), buccal (as snus)

Pharmacokinetic data

Bio availability

20 to 45% (oral)

Metabolism

hepatic

Half-life

2 hours; 20 hours active metabolite (cotinine)

Identifiers

CAS number

54-11-5 

ATC code

N07BA01 QP53AX13

PubChem

CID 942

IUPHAR ligand

2585

DrugBank

DB00184

ChemSpider

80863 

UNII

6M3C89ZY6R 

KEGG

D03365 

ChEBI

CHEBI:17688 

ChEMBL

CHEMBL3 

Chemical data

Formula

C10H14N2 

Mol. mass

162.12 g/mol

Physical data

Density

1.01 g/cm³

Melt. point

-79 °C (-110 °F)

Boiling point

247 °C (477 °F)

 



















































































Nicotine
is a potent parasympathomimetic alkaloid found in the nightshade family of plants (Solanaceae).
It acts as a nicotinic acetylcholine receptor agonist.
It is made in the roots and accumulates in the leaves of the plants.
It constitutes approximately 0.6–3.0% of the dry weight of tobacco and is present in the range of 2–7 µg/kg of various edible plants.
It functions as an anti herbivore chemical; therefore, nicotine was widely used as an insecticide in the past and nicotine analogs such as imidacloprid are currently widely used.
In smaller doses (an average cigarette yields about 1 mg of absorbed nicotine), the substance acts as a stimulant in mammals, while high amounts (30–60 mg) can be fatal.
This stimulant effect is likely a major contributing factor to the dependence-forming properties of tobacco smoking.
According to the American Heart Association, nicotine addiction has historically been one of the hardest addictions to break, while the pharmacological and behavioral characteristics that determine tobacco addiction are similar to those determining addiction to heroin and cocaine.
The nicotine content of popular American-brand cigarettes has slowly increased over the years, and one study found that there was an average increase of 1.78% per year between the years of 1998 and 2005.
This was found for all major market categories of cigarettes.
Research in 2011 has found that nicotine inhibits chromatin-modifying enzymes (class I and II histone deacetylases) which increases the ability of cocaine to cause an addiction.


Contents

History and name
Nicotine is named after the tobacco plant Nicotiana tabacum, which in turn is named after the French ambassador in Portugal, Jean Nicot de Villemain, who sent tobacco and seeds to Paris in 1560, and who promoted their medicinal use.
The tobacco and seeds were brought to ambassador Nicot from Brazil by Luis de Gois, a Portuguese colonist in São Paulo.
Nicotine was first isolated from the tobacco plant in 1828 by physician Wilhelm Heinrich Posselt and chemist Karl Ludwig Reimann of Germany, who considered it a poison
Its chemical empirical formula was described by Melsens in 1843, its structure was discovered by Adolf Pinner and Richard Wolffenstein in 1893, and it was first synthesized by Amé Pictet and A. Rotschy in 1904.


Historical use of nicotine as an insecticide
Tobacco was introduced to Europe in 1559, and by the late 17th century, it was used not only for smoking but also as an insecticide.
After World War II, over 2,500 tons of nicotine insecticide (waste from the tobacco industry) were used worldwide, but by the 1980s the use of nicotine insecticide had declined below 200 tons.
This was due to the availability of other insecticides that are cheaper and less harmful to mammals.
Currently, nicotine is a permitted pesticide for organic farming because it is derived from a botanical source.
Nicotine sulfate sold for use as a pesticide is labeled "DANGER," indicating that it is highly toxic.
However, in 2008, the EPA received a request to cancel the registration of the last nicotine pesticide registered in the United States.
This request was granted, and after 1 January 2014, this pesticide will not be available for sale.


Chemistry
Nicotine is a hygroscopic, oily liquid that is miscible with water in its base form.
As a nitrogenous base, nicotine forms salts with acids that are usually solid and water soluble, for example nicotine sulfate which, being a solid, is easier to handle in its use as an insecticide. (For retail use it is sold as solution in water ready for spraying.)
Its flash point is 95°C and its auto-ignition temperature is 244°C.


Optical activity
Nicotine is optically active, having two enantiomeric forms.
The naturally occurring form of nicotine is levorotatory with a specific rotation of [α]D = –166.4° ((−)-nicotine).
The dextrorotatory form, (+)-nicotine is physiologically less active than (–)-nicotine. (−)-nicotine is more toxic than (+)-nicotine.
The salts of (+)-nicotine are usually dextrorotatory.


Biosynthesis


Nicotine biosynthesis
The biosynthetic pathway of nicotine involves a coupling reaction between the two cyclic structures that compose nicotine.
Metabolic studies show that the pyridine ring of nicotine is derived from niacin (nicotinic acid) while the pyrrolidone is derived from N-methyl-Δ1-pyrrollidium cation
Biosynthesis of the two component structures proceeds via two independent syntheses, the NAD pathway for niacin and the tropane pathway for N-methyl-Δ1-pyrrollidium cation.
The NAD pathway in the genus nicotiana begins with the oxidation of aspartic acid into α-imino succinate by aspartate oxidase (AO).
This is followed by a condensation with glyceraldehyde-3-phosphate and a cyclization catalyzed by quinolinate synthase (QS) to give quinolinic acid.
Quinolinic acid then reacts with phosphoriboxyl pyrophosphate catalyzed by quinolinic acid phosphoribosyl transferase (QPT) to form niacin mononucleotide (NaMN).
The reaction now proceeds via the NAD salvage cycle to produce niacin via the conversion of nicotinamide by the enzyme nicotinamidase.
The N-methyl-Δ1-pyrrollidium cation used in the synthesis of nicotine is an intermediate in the synthesis of tropane-derived alkaloids.
Biosynthesis begins with decarboxylation of ornithine by ornithine decarboxylase (ODC) to produce putrescine.
Putrescine is then converted into N-methyl putrescine via methylation by SAM catalyzed by putrescine N-methyltransferase (PMT).
N-methylputrescine then undergoes deamination into 4-methylaminobutanal by the N-methylputrescine oxidase (MPO) enzyme, 4-methylaminobutanal then spontaneously cyclize into N-methyl-Δ1-pyrrollidium cation.
The final step in the synthesis of nicotine is the coupling between N-methyl-Δ1-pyrrollidium cation and niacin.
Although studies conclude some form of coupling between the two component structures, the definite process and mechanism remains undetermined.
The current agreed theory involves the conversion of niacin into 2,5-dihydropyridine through 3,6-dihydronicotinic acid.
The 2,5-dihydropyridine intermediate would then react with N-methyl-Δ1-pyrrollidium cation to form enantiomerically pure (–)-nicotine.


Pharmacology

Pharmacokinetics

Side effects of nicotine
As nicotine enters the body, it is distributed quickly through the bloodstream and crosses the blood, brain barrier reaching the brain within 10–20 seconds after inhalation.
The elimination half-life of nicotine in the body is around two hours.
The amount of nicotine absorbed by the body from smoking depends on many factors, including the types of tobacco, whether the smoke is inhaled, and whether a filter is used.
For chewing tobacco, dipping tobacco, snus and snuff, which are held in the mouth between the lip and gum, or taken in the nose, the amount released into the body tends to be much greater than smoked tobacco.
Nicotine is metabolized in the liver by cytochrome P450 enzymes (mostly CYP2A6, and also by CYP2B6).
A major metabolite is cotinine.
Other primary metabolites include nicotine N'-oxide, nornicotine, nicotine isomethonium ion, 2-hydroxynicotine and nicotine glucuronide.
Under some conditions, other substances may be formed such as myosmine.
Glucuronidation and oxidative metabolism of nicotine to cotinine are both inhibited by menthol, an additive to mentholated cigarettes, thus increasing the half-life of nicotine in vivo.


Detection of use

Medical detection
Nicotine can be quantified in blood, plasma, or urine to confirm a diagnosis of poisoning or to facilitate a medicolegal death investigation.
Urinary or salivary cotinine concentrations are frequently measured for the purposes of pre-employment and health insurance medical screening programs.
Careful interpretation of results is important, since passive exposure to cigarette smoke can result in significant accumulation of nicotine, followed by the appearance of its metabolites in various body fluids.
Nicotine use is not regulated in competitive sports programs, yet the drug has been shown to have a significant beneficial effect on athletic endurance in subjects who have not used nicotine before.


Pharmacodynamics
Nicotine acts on the nicotinic acetylcholine receptors, specifically the ganglion type nicotinic receptor and one CNS nicotinic receptor.
The former is present in the adrenal medulla and elsewhere, while the latter is present in the central nervous system (CNS).
In small concentrations, nicotine increases the activity of these receptors. Nicotine also has effects on a variety of other neurotransmitters through less direct mechanisms.


In the central nervous system

Effect of nicotine on dopaminergic neurons.
By binding to nicotinic acetylcholine receptors, nicotine increases the levels of several neurotransmitters, acting as a sort of "volume control".
It is thought that increased levels of dopamine in the reward circuits of the brain are responsible for the apparent euphoria and relaxation, and addiction caused by nicotine consumption.
Nicotine has a higher affinity for acetylcholine receptors in the brain than those, in skeletal muscle, though at toxic doses it can induce contractions and respiratory paralysis.
Nicotine's selectivity is thought to be due to a particular amino acid difference on these receptor subtypes.
Tobacco smoke contains anabasine, anatabine, and nornicotine.
It also contains the monoamine oxidase inhibitors harman and norharman.
These beta-carboline compounds significantly decrease MAO activity in smokers.
MAO enzymes break down monoaminergic neurotransmitters such as dopamine, norepinephrine, and serotonin.
It is thought that the powerful interaction between the MAOIs and the nicotine is responsible for most of the addictive properties of tobacco smoking.
The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats.
Chronic nicotine exposure via tobacco smoking up-regulates alpha4beta2* nAChR in cerebellum and brainstem regions but not habenulopeduncular structures.
Alpha4beta2 and alpha6beta2 receptors, present in the ventral tegmental area, play a crucial role in mediating the reinforcement effects of nicotine.


In the sympathetic nervous system
Nicotine also activates the sympathetic nervous system, acting via splanchnic nerves to the adrenal medulla, stimulates the release of epinephrine.
Acetylcholine released by preganglionic sympathetic fibers of these nerves acts on nicotinic acetylcholine receptors, causing the release of epinephrine (and noradrenaline) into the bloodstream.
Nicotine also has an affinity for melanin containing tissues due to its precursor function in melanin synthesis or due to the irreversible binding of melanin and nicotine. This has been suggested to underlie the increased nicotine dependence and lower smoking cessation rates in darker pigmented individuals.
However, further research is warranted before a definite conclusive link can be inferred.


In Adrenal Modulla

Effect of nicotine on chromaffin cells.
By binding to ganglion type nicotinic receptors in the adrenal medulla nicotine increases flow of adrenaline (epinephrine), a stimulating hormone and neurotransmitter.
By binding to the receptors, it causes cell depolarization and an influx of calcium through voltage-gated calcium channels.
Calcium triggers the exocytosis of chromaffin granules and thus the release of epinephrine (and norepinephrine) into the bloodstream.
The release of epinephrine (adrenaline) causes an increase in heart rate, blood pressure and respiration, as well as higher blood glucose levels.
Nicotine is the natural product of tobacco, having a half-life of 1 to 2 hours. Cotinine is an active metabolite of nicotine that remains in the blood for 18 to 20 hours, making it easier to analyze due to its longer half-life.


Psychoactive effects

Further information:

Psychoactive drug
Nicotine's mood altering effects are different by report: in particular it is both a stimulant and a relaxant
First causing a release of glucose from the liver and epinephrine (adrenaline) from the adrenal medulla, it causes stimulation.
Users report feelings of relaxation, sharpness, calmness, and alertness.
Like any stimulant, it may very rarely cause the often uncomfortable neuropsychiatric effect of akathisia.
By reducing the appetite and raising the metabolism, some smokers may lose weight as a consequence.
When a cigarette is smoked, nicotine-rich blood passes from the lungs to the brain within seven seconds and immediately stimulates the release of many chemical messengers such as acetylcholine, norepinephrine, epinephrine, vasopressin, histamine, arginine, serotonin, dopamine, autocrine agents, and beta-endorphin.
This release of neurotransmitters and hormones is responsible for most of nicotine's effects. Nicotine appears to enhance concentration and memory due to the increase of acetylcholine. It also appears to enhance alertness due to the increases of acetylcholine and norepinephrine. Arousal is increased by the increase of norepinephrine.
Pain is reduced by the increases of acetylcholine and beta-endorphin.
Anxiety is reduced by the increase of beta-endorphin.
Nicotine also extends the duration of positive effects of dopamine and increases sensitivity in brain reward systems.
Most cigarettes (in the smoke inhaled) contain 1 to 3 milligrams of nicotine.
Research suggests that, when smokers wish to achieve a stimulating effect, they take short quick puffs, which produce a low level of blood nicotine.
This stimulates nerve transmission.
When they wish to relax, they take deep puffs, which produce a high level of blood nicotine, which depresses the passage of nerve impulses, producing a mild sedative effect.
At low doses, nicotine potently enhances the actions of norepinephrine and dopamine in the brain, causing a drug effect typical of those of psychostimulants.
At higher doses, nicotine enhances the effect of serotonin and opiate activity, producing a calming, pain-killing effect. Nicotine is unique in comparison to most drugs, as its profile changes from stimulant to sedative/pain killer in increasing dosages and use.
Technically, nicotine is not significantly addictive, as nicotine administered alone does not produce significant reinforcing properties.
However, after co-administration with an MAOI, such as those found in tobacco, nicotine produces significant behavioral sensitization, a measure of addiction potential.
This is similar in effect to amphetamine.

A 21 mg patch applied to the left arm.
The Cochrane Collaboration finds that NRT increases a quitter's chance of success by 50 to 70%.
But in 1990, researchers found that 93% of users returned to smoking within six months
Nicotine gum, usually in 2-mg or 4-mg doses, and nicotine patches are available, as well as smokeless tobacco, nicotine lozenges and electronic cigarettes.

Side effects
Nicotine increases blood pressure and heart rate in humans.
Nicotine can stimulate abnormal proliferation of vascular endothelial cells, similar to that seen in atherosclerosis.
Nicotine induces potentially atherogenic genes in human coronary artery endothelial cells. Nicotine could cause microvascular injury through its action on nicotinic acetylcholine receptors (nAChRs), but other mechanisms are also likely at play.
A study on rats showed that nicotine exposure abolishes the beneficial and protective effects of estrogen on the hippocampus, an estrogen-sensitive region of the brain involved in memory formation and retention.

Dependence and withdrawal
See also: Smoking cessation
Modern research shows that nicotine acts on the brain to produce a number of effects. Specifically, research examining its addictive nature has been found to show that nicotine activates the mesolimbic pathway ("reward system") – the circuitry within the brain that regulates feelings of pleasure and euphoria.
Dopamine is one of the key neurotransmitters actively involved in the brain. Research shows that by increasing the levels of dopamine within the reward circuits in the brain, nicotine acts as a chemical with intense addictive qualities. In many studies it has been shown to be more addictive than cocaine and heroin.
Like other physically addictive drugs, nicotine withdrawal causes down-regulation of the production of dopamine and other stimulatory neurotransmitters as the brain attempts to compensate for artificial stimulation.
As dopamine regulates, the sensitivity of nicotinic acetylcholine receptors decreases.
To compensate for this compensatory mechanism, the brain in turn up regulates the number of receptors, convoluting its regulatory effects with compensatory mechanisms meant to counteract other compensatory mechanisms.
An example is the increase in norepinephrine, one of the successors to dopamine, which inhibit reuptake of the glutamate receptors, in charge of memory and cognition.
The net effect is an increase in reward pathway sensitivity, the opposite of other addictive drugs such as cocaine and heroin, which reduce reward pathway sensitivity.
This neuronal brain alteration can persist for months after administration ceases.
A study found that nicotine exposure in adolescent mice retards the growth of the dopamine system, thus increasing the risk of substance abuse during adolescence.
Some have been able to restart their natural dopamine production and bypass months or years of depression caused by nicotine withdrawal by using a combination of 2 over-the-counter supplements: 5-HTP (5-Hydroxytryptophan also known as oxitriptan) and L-Tyrosine (para-hydroxyphenylalanine). Studies of the combination have been conducted only on general depression and no one has yet measured the effects specifically on nicotine withdrawal-related depression.
However, anecdotal evidence suggests that the combination can be effective.
In addition to being a natural and low-cost alternative to prescription anti-depressants, this protocol also has the benefit of being short-term in that the treatment is only necessary for a few months after nicotine abatement.
Certain side effects, especially negative drug interactions, have been found with 5-HTP, so this treatment should not be undertaken in combination with any prescription medication or without specific approval from a doctor.

Immunology Prevention

A model of a nicotine molecule
Because of the severe addictions and the harmful effects of smoking, vaccination protocols have been developed.
The principle operates under the premise that if an antibody is attached to a nicotine molecule, it will be prevented from diffusing through the capillaries, thus making it less likely that it ever affects the brain by binding to nicotinic acetylcholine receptors.
These include attaching the nicotine molecule as a hapten to a protein carrier such as Keyhole limpet hemocyanin or a safe modified bacterial toxin to elicit an active immune response. Often it is added with bovine serum albumin.
Additionally, because of concerns with the unique immune systems of individuals being liable to produce antibodies against endogenous hormones and over the counter drugs, monoclonal antibodies have been developed for short term passive immune protection. They have half-lives varying from hours to weeks.
Their half-lives depend on their ability to resist degradation from pinocytosis by epithelial cells.

Toxicology

The LD50 of nicotine is 50 mg/kg for rats and 3 mg/kg for mice. 30–60 mg (0.5–1.0 mg/kg) can be a lethal dosage for adult humans.
Nicotine therefore has a high toxicity in comparison to many other alkaloids such as cocaine, which has an LD50 of 95.1 mg/kg when administered to mice.
It is unlikely that a person would overdose on nicotine through smoking alone, although overdose can occur through combined use of nicotine patches or nicotine gum and cigarettes at the same time
Spilling a high concentration of nicotine onto the skin can cause intoxication or even death, since nicotine readily passes into the bloodstream following dermal contact.
Historically, nicotine has not been regarded as a carcinogen and the IARC has not evaluated nicotine in its standalone form and assigned it to an official carcinogen group.
While no epidemiological evidence supports that nicotine alone acts as a carcinogen in the formation of human cancer, research over the last decade has identified nicotine's carcinogenic potential in animal models and cell culture.
Nicotine has been noted to directly cause cancer through a number of different mechanisms such as the activation of MAP Kinases.
Indirectly, nicotine increases cholinergic signalling (and adrenergic signalling in the case of colon cancer), thereby impeding apoptosis (programmed cell death), promoting tumor growth, and activating growth factors and cellular mitogenic factors such as 5-LOX, and EGF.
Nicotine also promotes cancer growth by stimulating angiogenesis and neovascularization.
In one study, nicotine administered to mice with tumors caused increases in tumor size (twofold increase), metastasis (nine-fold increase), and tumour recurrence (threefold increase).
The teratogenic properties of nicotine, has been investigated.
According to a study of ca. 77,000 pregnant women in Denmark, women who used nicotine gum and patches during the early stages of pregnancy were found to face an increased risk of having babies with birth defects.
The study showed that women who used nicotine-replacement therapy in the first 12 weeks of pregnancy had a 60% greater risk of having babies with birth defects compared to women who were non-smokers.
Nicotine use among pregnant women has also been correlated to increased frequency of ADHD. Children born to mothers who used tobacco were two and a half times more likely to be diagnosed with ADHD.
Froelich estimated that "exposure to higher levels of lead and prenatal tobacco each accounted for 500,000 additional cases of ADHD in U.S. children".
Effective April 1, 1990, the Office of Environmental Health Hazard Assessment (OEHHA) of the California Environmental Protection Agency added nicotine to the list of chemicals known to cause developmental toxicity

Therapeutic uses
The primary therapeutic use of nicotine is in treating nicotine dependence in order to eliminate smoking with the damage it does to health.
Controlled levels of nicotine are given to patients through gums, dermal patches, lozenges, electronic/substitute cigarettes or nasal sprays in an effort to wean them off their dependence.
However, in a few situations, smoking has been observed to be of therapeutic value. These are often referred to as "Smoker’s Paradoxes"
Although in most cases the actual mechanism is understood only poorly or not at all, it is generally believed that the principal beneficial action is due to the nicotine administered, and that administration of nicotine without smoking may be as beneficial as smoking, without the higher risk to health due to tar and other ingredients found in tobacco.
For instance, studies suggest that smokers require less frequent repeated revascularization after percutaneous coronary intervention (PCI).
Risk of ulcerative colitis has been frequently shown to be reduced by smokers on a dose-dependent basis; the effect is eliminated if the individual stops smoking.
Smoking also appears to interfere with development of Kaposi's sarcoma in patients with HIV.
Nicotine reduces the chance of preeclampsia, and atopic disorders such as allergic asthma.
A plausible mechanism of action in these cases may be nicotine acting as an anti-inflammatory agent, and interfering with the inflammation-related disease process, as nicotine has vasoconstrictive effects.
Tobacco smoke has been shown to contain compounds capable of inhibiting monoamine oxidase, which is responsible for the degradation of dopamine in the human brain.
When dopamine is broken down by MAO-B, neurotoxic by-products are formed, possibly contributing to Parkinson's and Alzheimers disease.
Many such papers regarding Alzheimer's disease and Parkinson's Diseasehave been published.
While tobacco smoking is associated with an increased risk of Alzheimer's disease, there is evidence that nicotine itself has the potential to prevent and treat Alzheimer's disease. Nicotine has been shown to delay the onset of Parkinson's disease in studies involving monkeys and humans.
A study has shown a protective effect of nicotine itself on neurons due to nicotine activation of α7-nAChR and the PI3K/Akt pathway which inhibits apoptosis-inducing factor release and mitochondrial translocation, cytochrome c release and caspase 3 activation.
Studies have indicated that nicotine can be used to help adults suffering from autosomal dominant nocturnal frontal lobe epilepsy.
The same areas that cause seizures in that form of epilepsy are responsible for processing nicotine in the brain.
Studies suggest a correlation between smoking and schizophrenia, with estimates near 75% for the proportion of schizophrenic patients who smoke.
Although the nature of this association remains unclear, it has been argued that the increased level of smoking in schizophrenia may be due to a desire to self-medicate with nicotine.
Other research found that mildly dependent users got some benefit from nicotine, but not those who were highly dependent.
Research at Duke University Medical Center found that nicotine may improve the symptoms of depression.
Nicotine appears to improve ADHD symptoms. Some studies have focused on benefits of nicotine therapy in adults with ADHD.
While acute/initial nicotine intake causes activation of nicotine receptors, chronic low doses of nicotine use leads to desensitisation of nicotine receptors (due to the development of tolerance) and results in an antidepressant effect, with research showing low dose nicotine patches being an effective treatment of major depressive disorder in non-smokers.
Nicotine (in the form of chewing gum or a transdermal patch) has been explored as an experimental treatment for OCD. Small studies show some success, even in otherwise treatment-refractory cases.
The relationship between smoking and inflammatory bowel disease has been firmly established, but remains a source of confusion among both patients and doctors.
It is negatively associated with ulcerative colitis but positively associated with Crohn's disease. In addition, it has opposite influences on the clinical course of the two conditions with benefit in ulcerative colitis but a detrimental effect in Crohn's disease.

In media
In some anti-smoking literature, the harm that tobacco smoking and nicotine addiction does is personified as Nick O'Teen, represented as a humanoid with some aspect of a cigarette or cigarette butt about him or his clothes.